Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).
Interview: Michael Farthing
14 Mins
Login to continue
Members
Create Account
Create your own personal healthcare feed, full of the latest content from across our divisions.
Register
